Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLPHINS-2: HM15912 in Adult Subjects with Short Bowel Syndrome-associated Intestinal Failure
2024-515160-32-00Phase 2Authorised
- Sponsor
- Hanmi Pharmaceutical
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 7
01
Overview
Phase 2, single-arm trial of sonefpeglutide in Short bowel syndrome-associated intestinal failure (SBS-IF), sponsored by Hanmi Pharmaceutical. Primary endpoints: Safety and tolerability of HM15912 over 24 weeks and Pharmacokinetic profile of HM15912. Planned start Aug 2024; status: authorised.
02
Drugs
sonefpeglutide
03
Conditions
Short bowel syndrome-associated intestinal failure (SBS-IF)
Beyond the preview
Go deeper on 2024-515160-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515160-32-00.